Boehringer Ingelheim is now accepting proposals for the 2022 Advancement in Equine Research Awards for Equine Respiratory Disease Research.
“Boehringer Ingelheim is committed to collaborating with the community of researchers, veterinarians and diagnosticians who dedicate their time and energy to improving the lives of horses through research,” said Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for Boehringer Ingelheim. “The Equine Research Awards program has been invaluable in advancing what we know about infectious respiratory disease and severe equine asthma syndrome.”
Public and private researchers in the United States, Canada and Mexico are eligible to submit proposals for research programs that help advance the diagnosis, treatment and understanding of equine disease. Boehringer Ingelheim will present five separate $15,000 awards focused on two specific disease topics—equine infectious respiratory disease and equine asthma syndrome.
Proposals must be submitted by September 15, 2022, and will be reviewed by an independent board consisting of renowned equine industry professionals, including practicing veterinarians and researchers. The board will peer review and select proposals based on probability of successfully completing the project, potential for impact to the equine industry, originality and scientific quality.
The awards will be announced at the 68th annual American Association of Equine Practitioners Convention, held November 18–22, 2022.
Again this year, Boehringer Ingelheim will accept electronic copies of the proposals in lieu of hard copies.
To participate in the 2022 awards program, submit an e-copy proposal, cover letter and Curriculum Vitae to Dr. Steve Grubbs at firstname.lastname@example.org.
The Boehringer Ingelheim Advancement in Equine Research Awards program was launched in 2011 to support veterinary research that results in practical applications for insights into important equine infectious and non-infectious diseases. More than $675,000 has been awarded to date for emerging science in equine research.
For more information and complete submission instructions, please click here.
About Boehringer Ingelheim Animal Health USA
Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention and treatment of diseases in animals. For veterinarians, pet owners, producers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock.
As a global leader in the animal health industry and as part of the family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.
Boehringer Ingelheim Animal Health has deep roots in the U.S. From a start in St. Joseph, Missouri, more than 100 years ago, it has grown to encompass seven sites.
Boehringer Ingelheim Animal Health’s portfolio contains widely used and well-respected vaccines, parasite-control products and therapeutics for pets, horses and livestock including NexGard, Heartgard, Pyramid Presponse, VAXXITEK, CircoFLEX® and Prascend®.
Learn more about Boehringer Ingelheim Animal Health USA at https://bi-animalhealth.com/.